American Peptide increases large-scale peptide capacity in California

American Peptide Company, a leading manufacturer of peptides and peptide conjugates, has expanded its state-of-the-art GMP peptide manufacturing facility in Southern California, US.

The two-phase expansion will increase the company’s large-scale peptide production capacity as well as enable it to continue to provide high quality peptides to its growing base of pharmaceutical and biotech customers.

The building work encompasses the construction of peptide purification and peptide synthesis suites. Four additional purification suites will be completed in the first phase and start operation in April 2009. New HPLC columns and tray lyophilisers are also included.

The second phase includes two additional large-scale synthesis suites for both solution and solid phase, with completion scheduled for Q2 in 2009.

This expansion includes 1,000 L to 2,000 L reactors for solution phase synthesis, in addition to the 260 L to 500 L SPPS for solid phase synthesis. Storage capacity will be doubled, and a 200 L tray lyophiliser will be installed to accommodate large-scale production.

‘As American Peptide Company continues to grow, we are investing in our production capacity to account for a larger customer base and bulk orders,’ said Takahiro Ogata, president and coo.

‘This facility expansion is yet another initiative we have implemented to meet our customers’ specific needs in the drug development and manufacturing process.’

American Peptide Company introduced its Total Peptide Management Programme last year, a customised service platform designed to help the pharma and life sciences industries bring new and innovative drugs to market faster. The programme offers a broad portfolio of peptides, value-added services, and expert consultation to support customer needs as drug products move from discovery to development and commercialisation.